Core Viewpoint - The report from Zhongyin International indicates that the revenue of CSPC Pharmaceutical Group increased by 6% quarter-on-quarter to 6.6 billion yuan, primarily due to the recovery from negative impacts on traditional oncology products, with sales growth across all core therapeutic areas [1] Financial Performance - Revenue for the third quarter reached 6.6 billion yuan, reflecting a 6% increase compared to the previous quarter [1] - Net profit decreased by 10% to 964 million yuan, attributed to a significant rise in operating expenses [1] Management Guidance - Management maintains guidance for a mid-single-digit recovery in performance for the second half of 2025 compared to the first half [1] - Despite the anticipated launch of innovative products and biosimilars in the first half of 2026, management expresses caution regarding the domestic market outlook due to uncertainties from upcoming national procurement renewals and strict control of medical insurance fund expenditures [1] Forecast Adjustments - The firm has kept its 2025 revenue forecast unchanged, but has lowered the revenue projections for 2026 and 2027 by 5.8% and 8.5% respectively, due to uncertainties surrounding the national procurement renewals and potentially slower-than-expected sales growth of new products [1] - The target price has been adjusted down to 8.5 HKD, while maintaining a "Hold" rating [1]

Core Viewpoint - Nomura's research report indicates that CSPC Pharmaceutical Group's revenue and profit for the first three quarters have decreased by 12.3% and 7.1% year-on-year, amounting to 19.9 billion and 3.5 billion respectively [1] Financial Performance - The estimated revenue for the third quarter is 6.6 billion, which represents a year-on-year increase of 3.4% and a quarter-on-quarter increase of 5.7%, significantly below the market expectation of 7.4 billion [1] - The year-on-year increase is primarily attributed to the recognition of collaboration income of 465 million, which was not present in the same period last year [1] - Product sales in the third quarter decreased by 2.7% year-on-year but increased by 4.2% quarter-on-quarter to 6.2 billion [1] Management Guidance - Management aims for positive growth in pharmaceutical sales by 2026 and anticipates that R&D spending will increase by 15% to 20% year-on-year during the same period [1] Forecast Adjustments - Nomura has revised down its revenue forecasts for 2025 and 2026 by 12% and 6% respectively, and profit forecasts by 26% and 14%, due to underperformance in pharmaceutical sales and delays in recognizing collaboration project income [1] - The target price has been reduced from 10.09 HKD to 9.11 HKD, while maintaining a "Buy" rating, with expectations for gradual sales recovery in the coming quarters [1]

Market Overview - The A-share market experienced a significant adjustment, with the Shanghai Composite Index falling below 3900 points and a decline exceeding 2% during the morning session [4][5] - The Shenzhen Component Index, ChiNext Index, and STAR Market 50 Index also saw declines of over 3% [5] - Major sectors such as comprehensive, non-ferrous metals, electric equipment, and basic chemicals faced declines exceeding 4% [5] - The lithium mining sector suffered a sharp drop, with a decline of over 7%, leading to a wave of stocks hitting the daily limit down [5] Agricultural Sector Performance - Despite the overall market downturn, agricultural stocks showed resilience, with companies like QiuLe Seed Industry and ShenNong Seed Industry seeing intraday gains exceeding 10% [6] New Stock Listing - A new stock, Dapeng Industrial, was listed today, experiencing a remarkable intraday increase of over 800%, closing with a gain of 664.56% at midday [7][8] - Dapeng Industrial specializes in precision cleaning equipment for the automotive powertrain and new energy systems, aligning with the trend of high-quality development in China's manufacturing sector [10]

Market Overview - A-shares experienced a significant adjustment, with the Shanghai Composite Index dropping below 3900 points and a decline exceeding 2% during the morning session [2] - The Shenzhen Component, ChiNext Index, and STAR Market 50 Index also saw declines of over 3% [2] - Major sectors such as comprehensive, non-ferrous metals, electric equipment, and basic chemicals faced declines exceeding 4% [2] Sector Performance - The lithium mining sector suffered a sharp decline, with a drop of over 7%, leading to a wave of stocks hitting the daily limit down [2] - Notable stocks in the lithium sector, including Dazhong Mining and Tibet Mining, experienced significant losses [2] - Conversely, the agricultural sector saw some stocks, such as Qiu Le Seed Industry and Shennong Seed Industry, rise by over 10% [2] New Stock Listing - The newly listed stock, Dapeng Industrial, saw its price surge by over 800% at one point, closing with a gain of 664.56% [3] - Dapeng Industrial specializes in precision cleaning equipment for the automotive and new energy sectors, aligning with the trend of high-quality development in China's manufacturing industry [3] Hong Kong Market - The Hong Kong stock market also faced a significant downturn, with the Hang Seng Index dropping over 2% [5] - Certain stocks, such as Shide Global, experienced a flash crash, with prices plummeting by 50% during the session [6] - Major sectors in Hong Kong, including healthcare, materials, and discretionary consumption, saw the largest declines [5]

在全球股市大幅调整之际，今天（11月21日）上午A股市场也出现调整。上证指数盘中跌破3900点。种业股逆势上涨，成为上午A股市场亮点之 一。 另外，A股市场今天有一只新股上市，为大鹏工业，上午盘中该股涨幅一度超过800%，截至午间收盘涨664.56%。 港股市场上午盘中亦大幅下跌。港股市场极少数个股出现闪崩走势。比如实德环球上午股价闪崩，盘中跌幅一度达到50%。 A股市场上午盘中大幅走低 种业股逆市上涨 在全球股市大幅调整之际，今天上午A股市场也出现调整。 上证指数今天上午低开，跌破3900点，盘中跌幅超过2%。深证成指、创业板指、科创50指数上午盘中跌幅均超过3%。 具体板块和赛道方面，若按照申万一级行业划分，各大板块呈现普跌态势，其中综合、有色金属、电力设备、基础化工等板块盘中跌幅超过4%。电子、通信、钢 铁、纺织服饰等板块盘中跌幅也居于市场前列。银行、传媒、农林牧渔等板块相对抗跌。 港股市场整体亦调整 有港股闪崩：股价盘中暴跌50% 港股市场上午盘中大幅下跌。 概念板块方面，锂矿概念板块重挫，盘中跌幅超过7%，板块内个股出现跌停潮。大中矿业、西藏矿业、金圆股份、盛新锂能等10多只股票盘中跌停。消息面上， ...

Market Overview - The Hong Kong stock market experienced fluctuations, with the Hang Seng Index closing at 23,831 points, down 145 points or 0.61% [1] - The market turnover decreased to 82.799 billion, with net inflows of 484 million from the Hong Kong Stock Connect [1] - The US stock market opened high but closed lower, with the Dow Jones down 0.84%, S&P 500 down 1.56%, and Nasdaq down 2.15% [2] Investment Opportunities - The report emphasizes the importance of selecting undervalued sectors and companies in the current market environment, particularly in the context of the Hong Kong stock market [3] - Key sectors to focus on include artificial intelligence, semiconductors, and industrial software, which are seen as new productivity drivers [3] - The report suggests that state-owned enterprises with lower valuations and higher dividends are also attractive investment options [3] Company Highlights - Baidu Group is highlighted for its AI strategy and recent stock performance, with a 2.4% increase despite market fluctuations [3][10] - The company reported a revenue of 32.713 billion yuan for Q2 2025, a year-on-year decrease of 3.59%, but a quarter-on-quarter increase of 0.80% [10] - Baidu's core revenue was 26.251 billion yuan, with a non-GAAP net profit of 4.792 billion yuan, reflecting a year-on-year decline of 34% [10] Sector Analysis - The report indicates that the real estate sector is stabilizing, with recent government measures aimed at promoting healthy market development [9] - The construction sector is expected to benefit from the Belt and Road Initiative, with recommendations to focus on leading state-owned enterprises like China Railway and China State Construction [9] - The report also notes the potential for growth in the upstream non-ferrous metals sector, benefiting from expectations of interest rate cuts by the Federal Reserve [3]

Group 1 - The Hong Kong stock market saw a collective decline in the innovative drug sector, with notable drops in several companies [1] - Three-Sixty Pharmaceutical experienced a decline of over 7% [1] - Other companies such as King’s Ray Biotechnology, CSPC Pharmaceutical Group, and Galenica also reported declines [1]

Core Insights - The report highlights Nvidia's strong quarterly performance with revenue reaching $57 billion, a year-on-year increase of 62% and a quarter-on-quarter increase of 22%, surpassing Bloomberg consensus estimates by 3% and guidance by 6% [2] - Nvidia's management provided a robust guidance for Q4, expecting revenue to reach $65 billion, which indicates a year-on-year growth of 65% and a quarter-on-quarter growth of 14%, significantly above market expectations [6] - The semiconductor industry is experiencing a shift towards AI applications, with companies like SK Hynix planning to increase DRAM production to meet the growing demand [5] Industry Commentary - The semiconductor industry, particularly Nvidia, is alleviating market concerns regarding an AI bubble through strong execution and guidance [6] - The report notes that Nvidia's gross margin for the quarter was 73.6%, slightly below consensus but higher than guidance, reflecting improvements in product mix and cost structure [2] - The report anticipates that the AI supply chain will continue to outperform the market until 2026, driven by strong demand for AI-related products [6] Company Analysis - NetEase reported a total revenue of RMB 28.4 billion for Q3 2025, an 8% year-on-year increase, although slightly below consensus expectations [6] - Palo Alto Networks achieved a revenue of $2.5 billion for Q1 FY26, a 15.7% year-on-year growth, exceeding consensus estimates [6] - Stone Pharmaceutical's revenue for the first three quarters of 2025 was RMB 19.9 billion, with a notable contribution from licensing income, indicating a sustainable growth trajectory [7][9]

Market Overview - The Hang Seng Index is expected to find short-term support around the 100-day moving average at approximately 25,600 points due to a hawkish stance from the Federal Reserve and ongoing uncertainties in the US-China trade relations [2] - The recent meeting between the US and Chinese leaders has led to a temporary easing of tensions, but core issues remain unresolved [2] - China's economic slowdown in Q3 has prompted the government to focus on expanding domestic demand and promoting technological self-reliance [2] Macro Focus - China is reportedly considering new support policies for the real estate sector, including interest subsidies for housing loans [4][10] - The government has announced a maximum funding of 400 million yuan to support 50 cities in developing new consumption models [10] - The US added 119,000 non-farm jobs in September, exceeding expectations, while the unemployment rate slightly increased to 4.4% [10] Corporate News - NetEase reported a 27% increase in adjusted profit for Q3, meeting expectations, but revenue growth of 8% fell short [5][11] - ByteDance's valuation has reportedly risen to $480 billion following a competitive auction for shares [11] - Xiaomi has produced its 500,000th vehicle in just 19 months, marking a significant milestone for the company [11] Sector Insights - The insurance sector is expected to benefit from strong investment returns in Q3 due to robust A-share performance [9] - Coal stocks are anticipated to see upward price momentum for thermal coal [9] - Lithium industry stocks are optimistic about a recovery in lithium carbonate demand, with supply and demand expected to balance [9]

Core Viewpoint - CICC maintains "outperform" rating for CSPC Pharmaceutical Group (01093), highlighting improvements in the company's prescription drug business and strong growth in respiratory and cardiovascular sectors [1] Performance Summary - For the first three quarters of 2025, the company reported revenue of 19.891 billion yuan, a year-over-year decrease of 12.3%, and a net profit attributable to shareholders of 3.511 billion yuan, down 7.1% year-over-year. Adjusted net profit was 3.079 billion yuan, a decline of 23.0% year-over-year, aligning with CICC's expectations. In Q3 2025, revenue reached 6.618 billion yuan, showing a year-over-year increase of 3.4% and a quarter-over-quarter increase of 5.7%, indicating stabilization in performance. The prescription drug revenue in Q3 2025 was 5.202 billion yuan, with year-over-year growth of 1.6% and quarter-over-quarter growth of 9.6% [2] Business Segment Performance - In Q3 2025, revenue from various therapeutic areas included: - Neurological diseases: 1.914 billion yuan (YoY -4.2%) - Oncology: 594 million yuan (YoY -47.2%) - Anti-infection: 826 million yuan (YoY -8.6%) - Cardiovascular diseases: 474 million yuan (YoY +17.8%) - Respiratory diseases: 320 million yuan (YoY +72.7%) - Digestive system: 248 million yuan (YoY +13.7%) - Other areas: 362 million yuan (YoY +25.6%) - The company’s raw material drug revenue was 1.415 billion yuan, with a year-over-year increase of 10.5% and a quarter-over-quarter decrease of 6.4% [2] R&D Progress - The company is advancing its innovation-driven strategy, with significant progress in its small nucleic acid pipeline. Key projects include PCSK9, expected to enter Phase III by the end of 2025, and other clinical projects targeting chronic diseases such as blood lipid and blood pressure management. The company is also exploring targeted delivery for eye, lung, fat, and muscle diseases. Notable in-development products include anti-HER2 monoclonal antibodies and EGFR ADCs [3] Overseas Business Development - The company is enhancing its business development strategy and has established an international licensing platform. In the first three quarters of 2025, it achieved licensing revenue of 1.540 billion yuan. In Q3 2025, the company licensed SYH2086 (an oral small molecule GLP-1) to Madrigal Pharmaceuticals for global development and commercialization outside of China, which includes an upfront payment of 120 million USD and potential milestone payments of up to 1.955 billion USD, along with double-digit sales royalties. The company has additional innovative products in its pipeline that are expected to lead to further licensing opportunities and milestone revenue recognition [4] Profit Forecast and Valuation - Considering increased R&D investments, CICC has lowered its net profit forecasts for 2025 and 2026 by 12% and 15% to 4.760 billion yuan and 5.353 billion yuan, respectively. The current stock price corresponds to a price-to-earnings ratio of 17.1 times for 2025 and 15.0 times for 2026. The "outperform" rating is maintained, with a target price reduction of 15% to 11.00 HKD, reflecting a price-to-earnings ratio of 24.4 times and 21.4 times for 2025 and 2026, respectively, indicating a potential upside of 42.5% [5]